Camp4 Therapeutics Corp adds veteran leader to accelerate regRNA-based therapy clinical push

Camp4 Therapeutics Corp adds veteran leader to accelerate regRNA-based therapy clinical push
Camp4 adds Michael MacLean

Camp4 Therapeutics Corp has announced the appointment of Michael MacLean to its Board of Directors. MacLean brings 35 years of expertise in financial and operational leadership to the company.

The appointment comes as Camp4 Therapeutics Corp advances its regRNA-based investigational therapy targeting SYNGAP1 toward clinical development. The company aims to leverage MacLean’s extensive industry experience as it navigates the transition from research to clinical trials.

Camp4 previously joined families at a SYNGAP1 Family Day event in Poland to share clinical updates with the patient community. The company has also presented its ASO platform for upregulating gene expression in SYNGAP1 and other diseases. These activities form part of Camp4's ongoing work to advance regRNA-based therapies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.